Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Large real-world pharmacovigilance study of 19,697 adverse event reports confirms known structure-toxicity relationships for ADCs, but lacks comparative efficacy data and uses observational methods without prospective controls.
Cost-utility analysis of a novel cancer therapy showing incremental QALY gain with high ICER; confirms clinical benefit translates to measurable quality-of-life improvement but at costs above conventional thresholds.
Retrospective multicenter study showing high response rates and 2-year survival outcomes for a high-risk CD5+ DLBCL population treated with Pola-R-CHP, with interim PET response predicting survival, but limited by small sample size, retrospective design, and short median follow-up.